StockDuty ← Dashboard Sep 15, 2026 10:45 PM ET
SignalFDA/Bio

GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy

GSK's $750M deal adds experimental blood cancer therapy, signaling biotech M&A catalyst.

GSK's $750M deal adds experimental blood cancer therapy, signaling biotech M&A catalyst.
GSK's $750M deal adds experimental blood cancer therapy, signaling biotech M&A catalyst. — impact context not separately stored; see What changed.
Sources